Ibrutinib-induced lymphocytosis in patients with chronic lymphocytic leukemia: correlative analyses from a phase II study

Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy

(2014) J. A. Woyach et al.   BLOOD

Egress of CD19+CD5+ cells into peripheral blood following treatment with the Bruton tyrosine kinase inhibitor ibrutinib in mantle cell lymphoma patients

(2013) B. Y. Chang et al.   BLOOD

Bruton's tyrosine kinase (BTK) function is important to the development and expansion of chronic lymphocytic leukemia (CLL)

(2013) J. A. Woyach et al.   BLOOD

BTK inhibition targets in vivo CLL proliferation through its effects on B-cell receptor signaling activity

(2013) S Cheng et al.   LEUKEMIA

Fostamatinib inhibits B-cell receptor signaling, cellular activation and tumor proliferation in patients with relapsed and refractory chronic lymphocytic leukemia

(2013) S E M Herman et al.   LEUKEMIA

Prognostic markers and their clinical applicability in chronic lymphocytic leukemia: where do we stand?

(2013) Richard Rosenquist et al.   LEUKEMIA & LYMPHOMA

Targeting pathological B cell receptor signalling in lymphoid malignancies

(2013) Ryan M. Young et al.   NATURE REVIEWS DRUG DISCOVERY

Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

(2013) Michael L. Wang et al.   NEW ENGLAND JOURNAL OF MEDICINE

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

(2013) John C. Byrd et al.   NEW ENGLAND JOURNAL OF MEDICINE

B-cell receptor signaling as a driver of lymphoma development and evolution

(2013) Carsten U. Niemann et al.   SEMINARS IN CANCER BIOLOGY

Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies

(2012) A. Agathangelidis et al.   BLOOD

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

(2012) A. Wiestner   BLOOD

The B-cell receptor signaling pathway as a therapeutic target in CLL

(2012) J. A. Woyach et al.   BLOOD

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

(2012) M. F. M. de Rooij et al.   BLOOD

Hyperleukocytosis, leukostasis and leukapheresis: Practice management

(2012) Chezi Ganzel et al.   BLOOD REVIEWS

Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging

(2012) Gianmario Sambuceti et al.   EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING

Bruton Tyrosine Kinase (BTK) and Its Role in B-cell Malignancy

(2012) Joseph J. Buggy et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Novel Targeted Agents and the Need to Refine Clinical End Points in Chronic Lymphocytic Leukemia

(2012) Bruce D. Cheson et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies

(2012) Adrian Wiestner   JOURNAL OF CLINICAL ONCOLOGY

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

(2012) Ranjana H. Advani et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting the B cell receptor pathway in chronic lymphocytic leukemia

(2012) Matthew S. Davids et al.   LEUKEMIA & LYMPHOMA

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

(2011) S. E. M. Herman et al.   BLOOD

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

(2011) S. Ponader et al.   BLOOD

B-cell receptor signaling in chronic lymphocytic leukemia

(2011) F. K. Stevenson et al.   BLOOD

Unknown

(2011) Carlo Calissano et al.   MOLECULAR MEDICINE

The lymph node microenvironment promotes B-cell receptor signaling, NF- B activation, and tumor proliferation in chronic lymphocytic leukemia

(2010) Y. Herishanu et al.   BLOOD

The splenomegaly of myeloproliferative and lymphoproliferative disorders: Splenic cellularity and vascularity

(2010) B. Zhang et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Improved Estimates of Cancer-Specific Survival Rates From Population-Based Data

(2010) Nadia Howlader et al.   JNCI-Journal of the National Cancer Institute

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

(2010) R. Eric Davis et al.   NATURE

In vivo intraclonal and interclonal kinetic heterogeneity in B-cell chronic lymphocytic leukemia

(2009) C. Calissano et al.   BLOOD

The microenvironment in mature B-cell malignancies: a target for new treatment strategies

(2009) J. A. Burger et al.   BLOOD

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

(2009) J. W. Friedberg et al.   BLOOD

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Patterns of liver infiltration in lymphoproliferative disease

(2008) D Baumhoer et al.   HISTOPATHOLOGY